Areas of activity

Therapeutic areas

We focus our activity in three therapeutic areas:


Within this area Biotest has developed products for the treatment of Haemophilia A and Haemophilia B which are disorders of the coagulation system.

People with Haemophilia lack certain factors in the blood (coagulation factor VIII or factor IX, respectively) which are vital in the process of blood clot formation and even small external or internal injuries can have serious consequences; which in extreme cases without correct, prompt treatment can be fatal.

Prophylaxis which consists of regular injections of the clotting factor (every two to three days) prevents bleeding from even starting – prophylaxis is usually carried out by the patient at home. With this type of treatment these patients can lead an essentially normal life. In the cases where patients are not on prophylactic treatment, factor VIII or factor IX preparations are used to stop the bleeding as and when it occurs.

Biotest is also developing a monoclonal antibody called Indatuximab Ravtansine (BT-062), for use in treating multiple myeloma as well as various other cancers (breast cancer, bladder cancer). This is described in more detail under “Research and development”

Clinical immunology

Biotest produces various immunoglobulin products for use in clinical immunology. They are used in the treatment and prophylaxis of disorders of the immune system which are either inherited or acquired (e.g. through infection or other diseases). In simple terms, immunoglobulin products replace the patients' missing antibodies and prevent infections caused by various pathogens.

Biotest has particular competence with hyperimmunoglobulins, these are immunoglobulin products with high concentrations of specific antibodies used in certain indications. One example is hepatitis B immunoglobulin – which are administered primarily before, during and directly after liver transplants which have been performed due to hepatitis B infection thus preventing re-infection.

This is described in more detail under “Research and development”.

Intensive care medicine

In intensive care and emergency medicine, plasma proteins manufactured by Biotest are used.  For example, Human Albumin solution can be used to correct for loss of blood volume and protein which can occur after serious injuries or especially burns. Another important therapeutic indication is severe bacterial infections (also known as sepsis) or severe lung infections. In this area in particular, special immunoglobulin preparations such as IgM concentrate which is still under development, directly save patients´ lives.